Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Gangolli Julian S
 2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2011		 3. Issuer Name and Ticker or Trading Symbol
ALLERGAN INC [AGN]
(Last)
(First)
(Middle)
2525 DUPONT DRIVE		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
CVP & Pres, North America
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

IRVINE, CA 92612		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 27,751.143 (1)
D
 
Common Stock 219.5814 (2)
I
By ESOP Trust
Common Stock 264.0416
I
By Wife's 401(k) plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)   (3) 02/02/2017 Common Stock 60,000 $ 58.55 D  
Employee Stock Option (Right to Buy)   (4) 02/14/2018 Common Stock 60,000 $ 64.47 D  
Employee Stock Option (Right to Buy)   (5) 02/20/2019 Common Stock 45,000 $ 40.16 D  
Employee Stock Option (Right to Buy)   (6) 02/22/2020 Common Stock 50,000 $ 59.13 D  
Employee Stock Option (Right to Buy)   (7) 02/17/2021 Common Stock 52,000 $ 75.58 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Gangolli Julian S
2525 DUPONT DRIVE
IRVINE, CA 92612		       CVP & Pres, North America  

Signatures

/s/ Matthew J. Maletta, attorney-in-fact for Mr. Gangolli 10/11/2011
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Includes shares acquired under the Allergan, Inc. Dividend Reinvestment Plan.
(2) Shares allocated to the reporting person's ESOP account as of reporting date.
(3) The option became exercisable in four equal annual installments beginning February 2, 2008.
(4) The option became exercisable in four equal annual installments beginning February 14, 2009.
(5) The option became exercisable in four equal annual installments beginning February 20, 2010. The remaining outstanding options for this award are reported in this filing.
(6) The option became exercisable in four equal annual installments beginning February 22, 2011.
(7) The option become exercisable in four equal annual installments beginning February 17, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.